https://www.biopharmawatch.com/news/PEN/thunder-study-penumbra-thunderbolt-stroke-care BiopharmaWatch en 2026-07-22T18:35:00.000Z THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care https://www.biopharmawatch.com/news/CHRS/coherus-oncology-q2-2026-financial-results BiopharmaWatch en 2026-07-22T17:36:00.000Z Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-renmark-roadshow-participation BiopharmaWatch en 2026-07-22T16:31:15.000Z Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series https://www.biopharmawatch.com/news/VALN/valneva-first-half-2026-financial-results BiopharmaWatch en 2026-07-22T15:45:00.000Z Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026 https://www.biopharmawatch.com/news/LLY/lilly-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-22T14:00:00.000Z Lilly confirms date and conference call for second-quarter 2026 financial results announcement https://www.biopharmawatch.com/news/OKYO/okyo-pharma-share-purchase-development-officer BiopharmaWatch en 2026-07-22T14:00:00.000Z OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director https://www.biopharmawatch.com/news/OLMA/xtraspin-casino-promo-codes-uk BiopharmaWatch en 2026-07-22T13:36:19.000Z XtraSpin Casino Promo Codes In The United Kingdom https://www.biopharmawatch.com/news/CPHI/china-pharma-pricing-5-million-offering BiopharmaWatch en 2026-07-22T13:25:00.000Z China Pharma Announces Pricing of $5 Million Registered Direct Offering https://www.biopharmawatch.com/news/MMED/minimed-flex-available-medicare-beneficiaries BiopharmaWatch en 2026-07-22T13:05:00.000Z MiniMed Flex™ Now Available to Medicare and Medicare Advantage Beneficiaries https://www.biopharmawatch.com/news/CODX/cosara-clinical-studies-tuberculosis-test-india BiopharmaWatch en 2026-07-22T13:00:00.000Z Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform https://www.biopharmawatch.com/news/CVS/cvs-health-strengthening-communities-massachusetts BiopharmaWatch en 2026-07-22T13:00:00.000Z CVS Health Helping to Strengthen Communities Across Massachusetts https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-next-gen-adc-opportunity BiopharmaWatch en 2026-07-22T12:40:00.000Z Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity https://www.biopharmawatch.com/news/ARTL/non-prescription-cbd-products-fall-short-art12-11 BiopharmaWatch en 2026-07-22T12:39:00.000Z New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition https://www.biopharmawatch.com/news/KAPA/kairos-pharma-bayer-collaboration-xofigo-prostate-cancer BiopharmaWatch en 2026-07-22T12:35:00.000Z Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer https://www.biopharmawatch.com/news/SRPT/sarepta-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-22T12:30:00.000Z Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SDGR/schrodinger-announces-q2-2026-results BiopharmaWatch en 2026-07-22T12:30:00.000Z Schrödinger to Announce Second Quarter 2026 Financial Results on August 5 https://www.biopharmawatch.com/news/PRGO/perrigo-second-quarter-2026-financial-results-release BiopharmaWatch en 2026-07-22T12:30:00.000Z Perrigo to Release Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/BIAF/bioaffinity-pictor-partnership-lung-diagnostics BiopharmaWatch en 2026-07-22T12:08:00.000Z bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD https://www.biopharmawatch.com/news/PFE/bluesight-pfizer-partner-rfid-medications-hospitals BiopharmaWatch en 2026-07-22T12:05:00.000Z Bluesight and Pfizer Partner to Provide Source-Tagged RFID Medications to Hospital Pharmacies https://www.biopharmawatch.com/news/LABT/lakewood-amendex-nu-3-resistance-data BiopharmaWatch en 2026-07-22T12:02:00.000Z Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria https://www.biopharmawatch.com/news/MCK/mckesson-quarterly-dividend-increase-2026 BiopharmaWatch en 2026-07-22T12:00:00.000Z McKesson Corporation Raises Quarterly Dividend by 15% to $0.94 Per Share https://www.biopharmawatch.com/news/DRIO/dario-announces-23-5-million-offering BiopharmaWatch en 2026-07-22T12:00:00.000Z Dario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/MNPR/monopar-rolling-nda-alxn1840-wilson-disease BiopharmaWatch en 2026-07-22T12:00:00.000Z Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease https://www.biopharmawatch.com/news/PCRX/pacira-report-q2-2026-results BiopharmaWatch en 2026-07-22T12:00:00.000Z Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026 https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-casey-tansey-retirement BiopharmaWatch en 2026-07-22T12:00:00.000Z Inspire Medical Systems, Inc. Announces Retirement of Casey M. Tansey from its Board of Directors https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-nova-2-trial-results-timing BiopharmaWatch en 2026-07-22T12:00:00.000Z LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-presentation-canaccord-conference BiopharmaWatch en 2026-07-22T11:40:00.000Z TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference https://www.biopharmawatch.com/news/USPH/us-physical-therapy-q2-2026-earnings-release BiopharmaWatch en 2026-07-22T11:30:00.000Z U.S. Physical Therapy, Inc. Schedules Second Quarter 2026 Earnings Release and Conference Call Dates https://www.biopharmawatch.com/news/ZTS/zoetis-launches-portela-reflovetmab-canada-eu BiopharmaWatch en 2026-07-22T11:30:00.000Z Zoetis Launches Portela® (relfovetmab) in Canada and the European Union https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-plozasiran-phase-3-results BiopharmaWatch en 2026-07-22T11:30:00.000Z Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia https://www.biopharmawatch.com/news/ZLAB/zai-lab-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-22T11:30:00.000Z Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 https://www.biopharmawatch.com/news/TRIB/trinity-biotech-latch-medical-collaboration-drug-delivery BiopharmaWatch en 2026-07-22T11:30:00.000Z Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology https://www.biopharmawatch.com/news/ZVRA/zevra-therapeutics-q2-2026-financial-results-call BiopharmaWatch en 2026-07-22T11:30:00.000Z Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call https://www.biopharmawatch.com/news/RADX/radiopharm-rad204-phase-1-trial-results BiopharmaWatch en 2026-07-22T11:05:00.000Z Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy https://www.biopharmawatch.com/news/QURE/uniqure-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-22T11:05:00.000Z uniQure to Announce Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/UTHR/united-therapeutics-q2-2026-financial-results BiopharmaWatch en 2026-07-22T11:00:00.000Z United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026 https://www.biopharmawatch.com/news/CNMD/conmed-airseal-robotic-solution-expansion BiopharmaWatch en 2026-07-22T11:00:00.000Z CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula https://www.biopharmawatch.com/news/HCSG/healthcare-services-group-q2-results-2023 BiopharmaWatch en 2026-07-22T11:00:00.000Z Healthcare Services Group Reports Second Quarter Results https://www.biopharmawatch.com/news/CSTL/castle-biosciences-canaccord-genuity-conference-2026 BiopharmaWatch en 2026-07-22T11:00:00.000Z Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/CRIS/curis-positive-emavusertib-update BiopharmaWatch en 2026-07-22T11:00:00.000Z Curis Announces Positive Emavusertib Update https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-btig-biotechnology-conference-2026 BiopharmaWatch en 2026-07-22T11:00:00.000Z Avalo Therapeutics to Participate in the BTIG Biotechnology Conference https://www.biopharmawatch.com/news/OKYO/okyo-pharma-cmo-share-purchase BiopharmaWatch en 2026-07-22T11:00:00.000Z OKYO Pharma Announces Purchase of Shares by Chief Medical Officer https://www.biopharmawatch.com/news/LAB/standard-bi-tools-q2-2026-results-announcement BiopharmaWatch en 2026-07-22T11:00:00.000Z Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-phase-2b-trial-results-rad101 BiopharmaWatch en 2026-07-22T11:00:00.000Z Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases https://www.biopharmawatch.com/news/GERN/geron-announces-q2-2026-financial-results BiopharmaWatch en 2026-07-22T11:00:00.000Z Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/BCRX/biocryst-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-22T11:00:00.000Z BioCryst to Report Second Quarter 2026 Financial Results on August 5 https://www.biopharmawatch.com/news/BDX/mike-garrison-retirement-bd BiopharmaWatch en 2026-07-22T10:55:00.000Z Mike Garrison to Retire from BD https://www.biopharmawatch.com/news/RPRX/neurimmune-sells-royalty-interest-cliramitug-royalty-pharma BiopharmaWatch en 2026-07-22T10:50:00.000Z Neurimmune sells a portion of its royalty interest in cliramitug to Royalty Pharma https://www.biopharmawatch.com/news/PHVS/bradykinin-b2-receptor-therapeutic-target BiopharmaWatch en 2026-07-22T10:50:00.000Z Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema https://www.biopharmawatch.com/news/SMMT/ivonescimab-phase-iii-harmoni-results BiopharmaWatch en 2026-07-22T10:30:00.000Z Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study https://www.biopharmawatch.com/news/RMTI/rockwell-medical-advances-leadership BiopharmaWatch en 2026-07-22T10:00:00.000Z Rockwell Medical Advances Quality and Regulatory Leadership https://www.biopharmawatch.com/news/NTRA/signatera-mrd-outperformed-amerk-merkel-cell-carcinoma BiopharmaWatch en 2026-07-22T10:00:00.000Z Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study https://www.biopharmawatch.com/news/GLSI/greenwich-lifesciences-flamingo-01-uk-expansion BiopharmaWatch en 2026-07-22T10:00:00.000Z Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom https://www.biopharmawatch.com/news/BLFS/repligen-acquire-biolife-solutions-cell-therapy BiopharmaWatch en 2026-07-22T10:00:00.000Z Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media https://www.biopharmawatch.com/news/RDNT/radnet-second-quarter-2026-financial-results-call BiopharmaWatch en 2026-07-22T10:00:00.000Z RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call https://www.biopharmawatch.com/news/BDSX/biodesix-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-22T10:00:00.000Z Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026 https://www.biopharmawatch.com/news/OLMA/greenluck-withdrawal-pending-meaning BiopharmaWatch en 2026-07-22T08:56:26.000Z Understanding The Greenluck Withdrawal Pending Meaning https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-upsized-public-offering BiopharmaWatch en 2026-07-22T02:46:00.000Z Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock https://www.biopharmawatch.com/news/PMI/picard-medical-reverse-stock-split-nyse-compliance BiopharmaWatch en 2026-07-22T00:48:00.000Z Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance https://www.biopharmawatch.com/news/TLX/tlx591-tx-prostact-select-study-results BiopharmaWatch en 2026-07-21T21:00:00.000Z TLX591-Tx ProstACT SELECT Study Published in Cancers Journal https://www.biopharmawatch.com/news/NUS/nu-skin-second-quarter-2026-results BiopharmaWatch en 2026-07-21T20:18:00.000Z Nu Skin Enterprises to Announce Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IMRX/atebimetinib-broad-activity-rass-raf-mutant-tumors BiopharmaWatch en 2026-07-21T20:15:09.000Z Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF-Bypass https://www.biopharmawatch.com/news/REVB/revelation-biosciences-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-07-21T20:05:00.000Z Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-conference-call-q2-2026 BiopharmaWatch en 2026-07-21T20:05:00.000Z Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates https://www.biopharmawatch.com/news/GILD/gilead-sciences-q2-2026-financial-results-release BiopharmaWatch en 2026-07-21T20:05:00.000Z Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 https://www.biopharmawatch.com/news/PIII/p3-health-partners-q2-2026-earnings-release BiopharmaWatch en 2026-07-21T20:05:00.000Z P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call https://www.biopharmawatch.com/news/PLSE/pulse-biosciences-q2-2026-financial-results-call BiopharmaWatch en 2026-07-21T20:05:00.000Z Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026 https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-samir-siddhanti-appointment BiopharmaWatch en 2026-07-21T20:05:00.000Z Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer https://www.biopharmawatch.com/news/TMDX/transmedics-report-q2-2026-results BiopharmaWatch en 2026-07-21T20:05:00.000Z TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026 https://www.biopharmawatch.com/news/KIDS/orthopediatrics-q2-2026-financial-results BiopharmaWatch en 2026-07-21T20:05:00.000Z OrthoPediatrics Corp. to Report Second Quarter Financial Results on August 4, 2026 https://www.biopharmawatch.com/news/NRIX/nurix-roche-bexobrutideg-collaboration BiopharmaWatch en 2026-07-21T20:01:00.000Z Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology https://www.biopharmawatch.com/news/CLDX/celldex-phase-2-barzolvolimab-prurigo-nodularis-results BiopharmaWatch en 2026-07-21T20:01:00.000Z Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis https://www.biopharmawatch.com/news/ACET/adicet-bio-fireside-chat-canaccord-genuity-conference BiopharmaWatch en 2026-07-21T20:00:00.000Z Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/CPHI/china-pharma-holdings-unusual-market-activity BiopharmaWatch en 2026-07-21T20:00:00.000Z China Pharma Holdings, Inc. Comments on Unusual Market Activity https://www.biopharmawatch.com/news/IMRX/david-freeman-joins-immuneering BiopharmaWatch en 2026-07-21T19:41:27.000Z David Freeman https://www.biopharmawatch.com/news/SNY/sanofi-executive-committee-evolution-strategic-chapter BiopharmaWatch en 2026-07-21T16:00:00.000Z Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter https://www.biopharmawatch.com/news/GILD/gilead-hiv-research-aids-2026 BiopharmaWatch en 2026-07-21T14:00:00.000Z Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure https://www.biopharmawatch.com/news/GILD/once-weekly-hiv-treatment-islatravir-lenacapavir BiopharmaWatch en 2026-07-21T14:00:00.000Z Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy https://www.biopharmawatch.com/news/IMRX/jennifer-cho-joins-immuneering BiopharmaWatch en 2026-07-21T13:59:23.000Z Jennifer Cho https://www.biopharmawatch.com/news/IMRX/jyoti-joshi-joins-immuneering BiopharmaWatch en 2026-07-21T13:45:33.000Z Jyoti Joshi https://www.biopharmawatch.com/news/CCRN/knox-lane-acquisition-cross-country-healthcare BiopharmaWatch en 2026-07-21T13:45:00.000Z Knox Lane Completes Acquisition of Cross Country Healthcare https://www.biopharmawatch.com/news/WGRX/wellgistics-health-changes-name-to-datameds-ai BiopharmaWatch en 2026-07-21T13:31:00.000Z WELLGISTICS HEALTH, INC. OFFICIALLY CHANGES CORPORATE NAME TO DATAMEDS AI, INC. https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-commercial-launch-update BiopharmaWatch en 2026-07-21T13:17:00.000Z Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption https://www.biopharmawatch.com/news/MYGN/myriad-genetics-firstgene-multiple-prenatal-screen-launch BiopharmaWatch en 2026-07-21T13:05:00.000Z Myriad Genetics Launches FirstGene® Multiple Prenatal Screen https://www.biopharmawatch.com/news/CVS/cvs-pet-medications-available-nationwide BiopharmaWatch en 2026-07-21T13:00:00.000Z Pet medications now available at CVS Pharmacy® https://www.biopharmawatch.com/news/HELP/helus-pharma-approach-study-enrollment-completed BiopharmaWatch en 2026-07-21T13:00:00.000Z A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening https://www.biopharmawatch.com/news/STXS/stereotaxis-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-21T13:00:00.000Z Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026 https://www.biopharmawatch.com/news/XGN/exagen-announces-q2-2026-financial-results BiopharmaWatch en 2026-07-21T13:00:00.000Z Exagen to Announce Second Quarter Financial Results on August 4, 2026 https://www.biopharmawatch.com/news/OKYO/okyo-pharma-presentation-hc-wainwright-ophthalmology-conference BiopharmaWatch en 2026-07-21T13:00:00.000Z OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference https://www.biopharmawatch.com/news/IMNN/imunon-positive-phase-2-mrd-data-imnn-001-ovarian-cancer BiopharmaWatch en 2026-07-21T13:00:00.000Z IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer https://www.biopharmawatch.com/news/SILO/silo-pharma-ai-agent-ptsd-drug-program BiopharmaWatch en 2026-07-21T12:55:00.000Z Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program https://www.biopharmawatch.com/news/TFX/teleflex-national-central-venous-access-agreement-premier BiopharmaWatch en 2026-07-21T12:44:00.000Z Teleflex Awarded National Central Venous Access Agreement with Premier, Inc. https://www.biopharmawatch.com/news/NAGE/niagen-bioscience-q2-2026-financial-results BiopharmaWatch en 2026-07-21T12:32:00.000Z Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 https://www.biopharmawatch.com/news/ATOS/atossa-therapeutics-presents-endoxifen-data-aacr-conference BiopharmaWatch en 2026-07-21T12:30:00.000Z Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers https://www.biopharmawatch.com/news/ZYBT/zhengye-biotechnology-unusual-trading-activity BiopharmaWatch en 2026-07-21T12:30:00.000Z Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity https://www.biopharmawatch.com/news/PPCB/propanc-biopharma-recombinant-trypsinogen-chymotrypsinogen BiopharmaWatch en 2026-07-21T12:30:00.000Z Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal https://www.biopharmawatch.com/news/MBOT/microbot-medical-showcases-robotic-technologies-srs-meeting BiopharmaWatch en 2026-07-21T12:30:00.000Z Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-fda-510k-submission-drug-screening BiopharmaWatch en 2026-07-21T12:30:00.000Z Intelligent Bio Solutions Completes Precision Testing, Strengthening FDA 510(k) Submission Package Ahead of Planned Entry into Multi-Billion-Dollar U.S. Drug Screening Market https://www.biopharmawatch.com/news/RKTO/rocket-one-expands-ai-infrastructure-partnership-placeve BiopharmaWatch en 2026-07-21T12:17:00.000Z Rocket One Expands AI Infrastructure Platform Through Strategic Partnership with Placeve to Advance Defense, Space, and Intelligent Edge Computing https://www.biopharmawatch.com/news/OLMA/i24slots-legit-ukgc-licensed BiopharmaWatch en 2026-07-21T12:05:35.000Z Is i24Slots Legit And UKGC Licensed For UK Players https://www.biopharmawatch.com/news/MXCT/maxcyte-genentech-cell-therapy-partnership BiopharmaWatch en 2026-07-21T12:05:00.000Z MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-q2-2026-financial-results BiopharmaWatch en 2026-07-21T12:05:00.000Z Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-partnering-process-cardiac-assets BiopharmaWatch en 2026-07-21T12:00:22.000Z Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation https://www.biopharmawatch.com/news/PGEN/precigen-announces-q2-2026-results-call BiopharmaWatch en 2026-07-21T12:00:00.000Z Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4 https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q2-2026-financial-results BiopharmaWatch en 2026-07-21T12:00:00.000Z Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 https://www.biopharmawatch.com/news/VRCA/verrica-medomie-exclusive-distribution-agreement-ycanth BiopharmaWatch en 2026-07-21T12:00:00.000Z Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel https://www.biopharmawatch.com/news/VYNE/vyne-therapeutics-reverse-stock-split-merger-update BiopharmaWatch en 2026-07-21T12:00:00.000Z VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience https://www.biopharmawatch.com/news/SNN/smith-nephew-asc-solutions-strategy BiopharmaWatch en 2026-07-21T12:00:00.000Z Smith+Nephew introduces expanded enterprise ASC Solutions Strategy to support growth, performance and value-based care https://www.biopharmawatch.com/news/CLDI/calidi-biotherapeutics-mid-year-update-future-drivers BiopharmaWatch en 2026-07-21T12:00:00.000Z Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-phase-2-renew-trial-enrolling BiopharmaWatch en 2026-07-21T12:00:00.000Z Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries https://www.biopharmawatch.com/news/NVO/novo-nordisk-lawsuit-against-eli-lilly-advertising BiopharmaWatch en 2026-07-21T11:35:00.000Z Novo Nordisk takes action to stop multiple misleading national GLP-1 advertising campaigns by Eli Lilly https://www.biopharmawatch.com/news/CGC/canopy-growth-participation-canaccord-genuity-conference BiopharmaWatch en 2026-07-21T11:30:00.000Z Canopy Growth Announces Participation at Upcoming Canaccord Genuity Growth Conference https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-webcast-fiscal-2026-results BiopharmaWatch en 2026-07-21T11:30:00.000Z Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results https://www.biopharmawatch.com/news/ABEO/cincinnati-childrens-activated-qualified-treatment-center-zevaskyn BiopharmaWatch en 2026-07-21T11:30:00.000Z Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN® https://www.biopharmawatch.com/news/CRON/cronos-sourz-spinach-expands-edibles-lineup BiopharmaWatch en 2026-07-21T11:30:00.000Z Cronos’ SOURZ by Spinach® Expands its Lineup of Edibles https://www.biopharmawatch.com/news/PSTV/plus-therapeutics-covers-cns-assay-ohio-kentucky BiopharmaWatch en 2026-07-21T11:30:00.000Z Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer https://www.biopharmawatch.com/news/PYPD/polypid-azurity-partnership-dplex100-commercialization BiopharmaWatch en 2026-07-21T11:30:00.000Z PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-btig-conference-2026 BiopharmaWatch en 2026-07-21T11:25:00.000Z Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026 https://www.biopharmawatch.com/news/JUNS/jupiter-neurosciences-signs-agreement-ala-002 BiopharmaWatch en 2026-07-21T11:13:00.000Z Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million https://www.biopharmawatch.com/news/AKTX/akari-therapeutics-whitehawk-collaboration BiopharmaWatch en 2026-07-21T11:05:00.000Z Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics https://www.biopharmawatch.com/news/WHWK/akari-therapeutics-whitehawk-collaboration BiopharmaWatch en 2026-07-21T11:05:00.000Z Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics https://www.biopharmawatch.com/news/PHIO/phio-pharmaceuticals-appoints-dr-todd-plott-board BiopharmaWatch en 2026-07-21T11:00:35.000Z Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors https://www.biopharmawatch.com/news/MDT/medtronic-touch-surgery-aide-ai-platform BiopharmaWatch en 2026-07-21T11:00:00.000Z A new era for surgery with real-time AI: Medtronic to unveil Touch Surgery™ Aide, the next-generation compute platform for the operating room at Society of Robotic Surgery 2026 https://www.biopharmawatch.com/news/CGEN/compugen-participate-btig-biotechnology-conference-2026 BiopharmaWatch en 2026-07-21T11:00:00.000Z Compugen to Participate in BTIG Biotechnology Conference 2026 https://www.biopharmawatch.com/news/NKTR/nektar-phase-3-zenith-ad-program-rezpegaldesleukin BiopharmaWatch en 2026-07-21T11:00:00.000Z Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis https://www.biopharmawatch.com/news/ACON/aclarion-nociscan-abstracts-aspen-meeting BiopharmaWatch en 2026-07-21T11:00:00.000Z Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice https://www.biopharmawatch.com/news/JUNS/pharmala-jupiter-license-agreement-ala-002 BiopharmaWatch en 2026-07-21T11:00:00.000Z PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 https://www.biopharmawatch.com/news/OKYO/okyo-pharma-chairman-share-purchase BiopharmaWatch en 2026-07-21T11:00:00.000Z OKYO Pharma Announces Purchase of Shares by Chairman https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-esmo-congress-2026 BiopharmaWatch en 2026-07-21T11:00:00.000Z Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026 https://www.biopharmawatch.com/news/TPST/tempest-senlang-collaboration-tpst-4003-car-t BiopharmaWatch en 2026-07-21T11:00:00.000Z Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T https://www.biopharmawatch.com/news/BNTX/biontech-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-21T10:45:00.000Z BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026 https://www.biopharmawatch.com/news/HSIC/henry-schein-q2-2026-conference-call-webcast BiopharmaWatch en 2026-07-21T10:30:00.000Z Henry Schein to Webcast Second Quarter 2026 Conference Call on Tuesday, August 4, 2026, at 8:00 a.m. ET https://www.biopharmawatch.com/news/STVN/stevanato-group-q2-2026-financial-results BiopharmaWatch en 2026-07-21T10:30:00.000Z Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026 https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-symon-ii-enrollment-completion BiopharmaWatch en 2026-07-21T10:30:00.000Z Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study https://www.biopharmawatch.com/news/MRK/phanes-merck-clinical-trial-expansion-spevatamig BiopharmaWatch en 2026-07-21T10:00:00.000Z Phanes Therapeutics Announces Expansion of Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate Spevatamig in Combination with KEYTRUDA® (Pembrolizumab) and Chemotherapy for Treatment of Biliary Tract Cancer https://www.biopharmawatch.com/news/NUTX/nutex-health-q2-2026-financial-results-call BiopharmaWatch en 2026-07-21T09:30:00.000Z Nutex Health Schedules 2026 Second Quarter Financial Results Release and Conference Call https://www.biopharmawatch.com/news/TLX/psma-pet-imaging-prostate-cancer-gallium-68 BiopharmaWatch en 2026-07-21T07:36:38.000Z PSMA-PET imaging for prostate cancer: Exploring gallium-68 in clinical practice https://www.biopharmawatch.com/news/IPHA/innate-pharma-completes-enrollment-phase-1-iph4502 BiopharmaWatch en 2026-07-21T05:00:00.000Z Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC) https://www.biopharmawatch.com/news/NVS/novartis-q2-2026-sales-growth-pipeline-advancements BiopharmaWatch en 2026-07-21T05:00:00.000Z Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed https://www.biopharmawatch.com/news/TLX/telix-q2-revenue-strong-momentum-pipeline-progress BiopharmaWatch en 2026-07-20T23:31:00.000Z Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress https://www.biopharmawatch.com/news/DARE/dare-bioscience-virtual-bus-tour-webinar-series BiopharmaWatch en 2026-07-20T22:48:43.000Z Press Release: Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities https://www.biopharmawatch.com/news/TLX/telix-q2-2026-revenue-update BiopharmaWatch en 2026-07-20T22:41:39.000Z Telix Q2 2026 Revenue US$247M, Strong Momentum and Pipeline Progress https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-psychedelic-biotech-approach BiopharmaWatch en 2026-07-20T22:04:20.000Z Joseph Tucker, Ph.D., CEO & Director, Enveric Biosciences [Big4Bio] https://www.biopharmawatch.com/news/ELDN/type-1-diabetes-pipeline-insulin-independence BiopharmaWatch en 2026-07-20T21:49:21.000Z Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence https://www.biopharmawatch.com/news/NEO/neogenomics-settlement-voluntary-disclosure-oig-hhs BiopharmaWatch en 2026-07-20T21:23:00.000Z NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS https://www.biopharmawatch.com/news/TLX/telix-first-patient-phase-3-luteon-trial-renal-cancer BiopharmaWatch en 2026-07-20T21:00:00.000Z Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Txfor Renal Cancer https://www.biopharmawatch.com/news/TLX/telix-doses-first-patient-luteon-trial-tlx250-tx BiopharmaWatch en 2026-07-20T21:00:00.000Z Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer https://www.biopharmawatch.com/news/CAH/cardinal-health-home-care-acquisitions BiopharmaWatch en 2026-07-20T20:45:00.000Z Cardinal Health expands home care business with two tuck-in acquisitions https://www.biopharmawatch.com/news/AHCO/adapthealth-divests-diabetes-health-business-cardinal-health BiopharmaWatch en 2026-07-20T20:30:00.000Z AdaptHealth Corp. Enters into Definitive Agreement to Divest Diabetes Health Business to Cardinal Health https://www.biopharmawatch.com/news/CLDI/calidi-reverse-stock-split-july-2026 BiopharmaWatch en 2026-07-20T20:30:00.000Z Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 https://www.biopharmawatch.com/news/BKD/brookdale-q2-2026-earnings-release-conference-call BiopharmaWatch en 2026-07-20T20:15:00.000Z Brookdale Announces Second Quarter 2026 Earnings Release and Conference Call Dates https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-second-quarter-results-2026 BiopharmaWatch en 2026-07-20T20:15:00.000Z Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 https://www.biopharmawatch.com/news/SIBN/si-bone-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-20T20:09:00.000Z SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026 https://www.biopharmawatch.com/news/STIM/neuronetics-appoints-nir-naor-cfo-management-changes BiopharmaWatch en 2026-07-20T20:05:00.000Z Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes https://www.biopharmawatch.com/news/RANI/rani-therapeutics-inducement-grant-cfo BiopharmaWatch en 2026-07-20T20:05:00.000Z Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/CBLL/ceribell-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-20T20:05:00.000Z Ceribell to Report Second Quarter 2026 Financial Results on August 10, 2026 https://www.biopharmawatch.com/news/TELA/tela-bio-second-quarter-2026-financial-results BiopharmaWatch en 2026-07-20T20:05:00.000Z TELA Bio to Announce Second Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MRVI/trilink-biotechnologies-new-patent-china-cleancap-technology BiopharmaWatch en 2026-07-20T20:02:00.000Z TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology https://www.biopharmawatch.com/news/ARCT/arcturus-therapeutics-canaccord-growth-conference BiopharmaWatch en 2026-07-20T20:01:00.000Z Arcturus Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference https://www.biopharmawatch.com/news/COSM/cosmos-health-expands-pharma-cell-partnership-albania BiopharmaWatch en 2026-07-20T19:46:00.000Z Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units